Clinical trials and equitable care pathways are needed to build on early evidence of benefit Substance use disorders (SUDs) ...

Novo Nordisk (NVO) plans to run studies on how its GLP-1 class of weight loss/diabetes drug can help people deal with addiction, Martin Holst Lange, the Danish pharma’s head of development, told an ...

Research suggests the drugs have potential for prevention and harm reduction in substance use disorders, writes Ziyad Al-Aly People taking glucagon-like peptide-1 (GLP-1) receptor agonists often ...

People struggling with many addictions, ranging from opioids to gambling, are reporting similar experiences in clinics, on ...

The US Food and Drug Administration has reported shortages of the GLP-1 medications Ozempic, Wegovy and Mounjaro at various dosages over the past year as drugmakers have raced to keep up with ...

A $350 genetic test developed by researchers at Mayo Clinic in Rochester, Minn., and subsequently licensed to Phenomic Sciences, seeks to assign risk scores to patients regarding their likelihood of ...

Phenomix's MyPhenome test continues to demonstrate predictive accuracy in identifying which patients are most likely to respond to GLP-1 therapies such as semaglutide. Studies presented at Obesity ...

SAN DIEGO, March 23, 2025 — Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss. Unfortunately, shortages and high costs have ...

Share on Pinterest A new generic of the GLP-1 drug Victoza, which is similar to popular medications like Ozempic, Wegovy, Mounjaro, and Zepbound, is now available in the United States.

A November 2025 Kaiser Family Foundation poll found that 1 in 8 U.S. adults have tried a GLP-1 medication for weight loss, diabetes or another condition. And we expect that number to rise now that one ...